Abstrak: Mendelian randomization (MR) is a method for estimating the causal relationship between an exposure and an outcome using a genetic factor as an instrumental variable (IV) for the exposure. In the traditional MR setting, data on the IV, exposure, and outcome are available for all participants. However, obtaining complete exposure data may be difficult in some settings, due to high measurement costs or lack of appropriate biospecimens. We used simulated data sets to assess statistical power and bias for MR when exposure data are available for a subset (or an independent set) of participants. We show that obtaining exposure data for a subset of participants is a cost-efficient strategy, often having negligible effects on power in comparison with a traditional complete-data analysis. The size of the subset needed to achieve maximum power depends on IV strength, and maximum power is approximately equal to the power of traditional IV estimators. Weak IVs are shown to lead to bias towards the null when the subsample is small and towards the confounded association when the subset is relatively large. Various approaches for confidence interval calculation are considered. These results have important implications for reducing the costs and increasing the feasibility of MR studies.

Abstrak: Prevention and treatment of common noncommunicable chronic diseases have been revolutionized by the development of therapies. Recently, several randomized controlled trials (RCTs) designed to assess the efficacy of new therapies targeted at well-established risk factors for noncommunicable chronic diseases have reported lower benefits than expected. Subsequent observational analysis of the same trial data has not clarified these unexpected findings. Mendelian randomization (MR) provides an approach for estimating causal effects from observational or trial data and thus provides information complementary to that from an RCT. An RCT assesses the efficacy of a therapy but does not usually confirm the underlying mechanistic pathway. In contrast, an MR study does not assess the efficacy of a therapy but rather assesses causal effects on an underlying mechanistic pathway. We suggest that incorporating an MR study into an RCT at the design stage would improve etiologic understanding of current therapies and enhance the search for therapies for the significant amount of noncommunicable chronic diseases that resists current treatments.

Abstrak: We show that, in the presence of uncontrolled environmental confounding, joint tests for the presence of a main genetic effect and gene-environment interaction will be biased if the genetic and environmental factors are correlated, even if there is no effect of either the genetic factor or the environmental factor on the disease. When environmental confounding is ignored, such tests will in fact reject the joint null of no genetic effect with a probability that tends to 1 as the sample size increases. This problem with the joint test vanishes under gene-environment independence, but it still persists if estimating the gene-environment interaction parameter itself is of interest. Uncontrolled environmental confounding will bias estimates of gene-environment interaction parameters even under gene-environment independence, but it will not do so if the unmeasured confounding variable itself does not interact with the genetic factor. Under gene-environment independence, if the interaction parameter without controlling for the environmental confounder is nonzero, then there is gene-environment interaction either between the genetic factor and the environmental factor of interest or between the genetic factor and the unmeasured environmental confounder. We evaluate several recently proposed joint tests in a simulation study and discuss the implications of these results for the conduct of gene-environment interaction studies.